Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Alp Serhat Kahveci
Sofosbuvir and Velpatasvir: A Complete Pan-Genotypic Treatment for HCV Patients
Turkish Journal of Gastroenterology
Gastroenterology
Related publications
Benefit-Risk Assessment for Sofosbuvir/Velpatasvir/Voxilaprevir Based on Patient Population and HCV Genotype: FDA's Evaluation
Hepatology
Medicine
Hepatology
Sofosbuvir, a Significant Paradigm Change in HCV Treatment
Journal of Clinical and Translational Hepatology
Sofosbuvir/Velpatasvir for Chronic Hepatitis C Infection in Patients With Transfusion-Dependent Thalassemia
American Journal of Hematology
Hematology
Secondary Occult Hepatitis C Virus Infection (HCV) in Chronic HCV Patients After Treatment With Sofosbuvir and Daclatasvir
International Journal of Current Microbiology and Applied Sciences
Ledipasvir and Sofosbuvir for HCV-infection in Patients Coinfected With HBV
Antiviral Therapy
Infectious Diseases
Pharmacology
SVR12 Rates Higher Than 99% After Sofosbuvir/Velpatasvir Combination in HCV Infected Patients With F0-F1 Fibrosis Stage: A Real World Experience
PLoS ONE
Multidisciplinary
Editorial: Genotype 3 HCV-who Still Needs Ribavirin in a Pan-Genotypic Era?
Alimentary Pharmacology and Therapeutics
Hepatology
Pharmacology
Gastroenterology
Cost Effectiveness Analysis of Sofosbuvir and Ledipasvir/Sofosbuvir in Hepatitis C Virus (HCV) Patients
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Editorial: Genotype 3 HCV-who Still Needs Ribavirin in a Pan-Genotypic Era? Authors’ Reply
Alimentary Pharmacology and Therapeutics
Hepatology
Pharmacology
Gastroenterology